Form 4: BioCorRx Director Luisa Ingargiola Receives Shares as Compensation

Director Luisa Ingargiola received shares of BioCorRx Inc. as compensation for her services, according to a recent SEC filing.

Summary

• Luisa Ingargiola, a director at BioCorRx Inc., received shares of the company's common stock as compensation for her services.
• On March 28, 2024, she acquired 5,566 shares at $0.00, increasing her holdings to 53,987 shares.
• On June 28, 2024, she acquired 10,204 shares at $0.00, further increasing her holdings to 64,191 shares.
• These shares were issued under a Director Agreement dated March 1, 2019, where she receives shares equivalent to $5,000 per fiscal quarter.
• The share issuance is based on the average closing price of the company's common stock for the three trading days immediately preceding the last day of each fiscal quarter.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects routine director compensation. The increased equity stake could be seen as a positive sign of alignment, but it's not a major market-moving event.

Positives

• The director's compensation structure aligns her interests with the company's performance.
• The director is incentivized to contribute to the company's success through equity ownership.

Industry Context

This type of equity compensation is common for directors of publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Director compensation packages vary widely across the pharmaceutical and biotechnology industries.
• Companies like Amgen and Gilead Sciences often provide a mix of cash and stock options to their directors, while smaller companies like BioCorRx may rely more heavily on stock grants due to cash constraints.
• The value of equity grants as a percentage of total compensation is a key metric to compare across companies of similar size and stage of development.

Related Party Transactions

• The issuance of shares to Luisa Ingargiola under the Director Agreement constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the director's increased equity stake as a positive sign of alignment with their interests.
• The issuance of new shares could have a slightly dilutive effect on existing shareholders.

Key Dates

Keywords

BioCorRx, Director Compensation, Share Acquisition, Luisa Ingargiola, SEC Form 4, Equity, BICX